
Nienke A De Glas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1605103/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands – A comparison of two national prospective longitudinal multi-centre cohort studies. European Journal of Cancer, 2022, 163, 189-199.	2.8	5
2	Geriatric assessment and treatment outcomes in a Dutch cohort of older patients with potentially curable esophageal cancer. Acta OncolÃ ³ gica, 2022, 61, 459-467.	1.8	5
3	Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer. Breast Cancer Research and Treatment, 2022, 193, 567-577.	2.5	10
4	Design and rationale of a routine clinical care pathway and prospective cohort study in older patients needing intensive treatment. BMC Geriatrics, 2021, 21, 29.	2.7	12
5	Prediction of Other-Cause Mortality in Older Patients with Breast Cancer Using Comorbidity. Cancers, 2021, 13, 1627.	3.7	7
6	Toxicity, response, and survival in older adults with metastatic melanoma treated with checkpoint inhibitors Journal of Clinical Oncology, 2021, 39, 9544-9544.	1.6	0
7	Predicting disease-related and patient-reported outcomes in older patients with breast cancer - a systematic review. Journal of Geriatric Oncology, 2021, 12, 696-704.	1.0	9
8	Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors. Cancers, 2021, 13, 2826.	3.7	11
9	Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative. Lancet Oncology, The, 2021, 22, e29-e36.	10.7	71
10	Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study. The Lancet Healthy Longevity, 2021, 2, e704-e711.	4.6	14
11	Geriatric Oncology: From Research to Clinical Practice. Cancers, 2021, 13, 5720.	3.7	0
12	Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review. Cancers, 2021, 13, 6366.	3.7	10
13	Perspectives on geriatric oncology research presented at the 2019 ESMO Congress. Journal of Geriatric Oncology, 2020, 11, 543-548.	1.0	0
14	Anticancer drugs are not well tolerated in all older patients with cancer. The Lancet Healthy Longevity, 2020, 1, e43-e47.	4.6	31
15	Geriatric Oncology: From Research to Clinical Practice. Cancers, 2020, 12, 3279.	3.7	2
16	Early stage breast cancer treatment and outcome of older patients treated in an oncogeriatric care and a standard care setting: an international comparison. Breast Cancer Research and Treatment, 2020, 184, 519-526.	2.5	2
17	Metastatic breast cancer in older patients: A longitudinal assessment of geriatric outcomes. Journal of Geriatric Oncology, 2020, 11, 969-975.	1.0	11
18	Caring for older patients with cancer during the COVID-19 pandemic: A Young International Society of Geriatric Oncology (SIOG) global perspective. Journal of Geriatric Oncology, 2020, 11, 1175-1181.	1.0	25

NIENKE A DE GLAS

#	Article	IF	CITATIONS
19	Impact of Older Age and Comorbidity on Locoregional and Distant Breast Cancer Recurrence: A Large Population-Based Study. Oncologist, 2020, 25, e24-e30.	3.7	15
20	Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper. Journal of Geriatric Oncology, 2019, 10, 389-397.	1.0	20
21	Improved survival of older patients with advanced breast cancer due to an increase in systemic treatments: a population-based study. Breast Cancer Research and Treatment, 2019, 178, 141-149.	2.5	11
22	Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer. Drugs and Aging, 2019, 36, 927-938.	2.7	74
23	Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer. Breast Cancer Research and Treatment, 2019, 178, 637-645.	2.5	10
24	HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology. Journal of Geriatric Oncology, 2019, 10, 1003-1013.	1.0	40
25	Are Older Patients with Cervical Cancer Managed Differently to Younger Patients? An International Survey. Cancers, 2019, 11, 1955.	3.7	7
26	What Every Oncologist Should Know About Geriatric Assessment for Older Patients With Cancer: Young International Society of Geriatric Oncology Position Paper. Journal of Oncology Practice, 2018, 14, 85-94.	2.5	120
27	Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591880961.	3.2	44
28	Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives. Expert Opinion on Investigational Drugs, 2018, 27, 787-801.	4.1	15
29	Global geriatric oncology: Achievements and challenges. Journal of Geriatric Oncology, 2017, 8, 374-386.	1.0	76
30	A Prospective Comparison of Younger and Older Patients' Preferences for Adjuvant Chemotherapy and Hormonal Therapy in Early Breast Cancer. Clinical Breast Cancer, 2016, 16, 379-388.	2.4	33
31	Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. Journal of Clinical Oncology, 2016, 34, 2366-2371.	1.6	497
32	Physical Functioning in Older Patients With Breast Cancer: A Prospective Cohort Study in the TEAM Trial. Oncologist, 2016, 21, 946-953.	3.7	35
33	The influence of insulinâ€like Growth Factorâ€1â€Receptor expression and endocrine treatment on clinical outcome of postmenopausal hormone receptor positive breast cancer patients: A Dutch TEAM substudy analysis. Molecular Oncology, 2016, 10, 509-516.	4.6	12
34	Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients. Journal of the National Cancer Institute, 2016, 108, djv366.	6.3	79
35	Authors' reply to Tabar and Kopans. BMJ, The, 2014, 349, g6828-g6828.	6.0	0
36	Physical activity and survival of postmenopausal, hormone receptor–positive breast cancer patients: Results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study. Cancer, 2014, 120, 2847-2854.	4.1	37

NIENKE A DE GLAS

#	Article	lF	CITATIONS
37	Validity of Adjuvant! Online program in older patients with breast cancer: a population-based study. Lancet Oncology, The, 2014, 15, 722-729.	10.7	81
38	Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study. BMJ, The, 2014, 349, g5410-g5410.	6.0	42
39	Impact of comorbidity on outcome of older breast cancer patients: a FOCUS cohort study. Breast Cancer Research and Treatment, 2014, 145, 185-192.	2.5	48
40	Survival after lumpectomy and mastectomy for early stage invasive breast cancer: The effect of age and hormone receptor status. Cancer, 2013, 119, 3253-3254.	4.1	7